• CureVac NV CVAC.OQ reported a quarterly adjusted loss of 23 cents​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of -31 cents. The mean expectation of two analysts for the quarter was for a loss of 19 cents per share. Wall Street expected results to range from -24 cents to -14 cents per share.

• Revenue fell 92.8% to €893.00 thousand from a year ago; analysts expected €6.68 million.

• CureVac NV's reported EPS for the quarter was a loss of 23 cents​.

• The company reported a quarterly loss of €51.66 million.

• CureVac NV shares had risen by 54.5% this quarter and gained 25.5% so far this year.

FORECAST CHANGES

• In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 2 "hold" and 1 "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for CureVac NV is $6.75

This summary was machine generated from LSEG data May 21 at 04:13 p.m. UTC. ​All figures in euros unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)